1. SK Life Science Inc YKP3089 C021 Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects with Partial Onset Seizures

Objective: To evaluate the safety and pharmacokinetics of YKP3089

Inclusion criteria

Age 14-65
Diagnosis of refractory focal epilepsy. No exact seizure frequency required.
Treated with at least one AED in the last 2

Exclusion criteria

History of any drug-induced rash or hypersensitivity reaction.

Contact
Mid-Atlantic Epilepsy & Sleep Center
Pavel Klein, M.D.
Ivana Tyrlikova, Arkady Barber, Lenka Goldman, study coordinators
Phone: 301 530 9744
Fax: 301 530 0046

The support That Sunovion Pharmaceuticals, Inc. has given the Private Practice Consortium is greatly appreciated.